VCEL

Vericel Corp (VCEL) 2025 Annual Report Summary

Business Context and Reporting Period

This summary covers Vericel Corporation's Form 10-K for the fiscal year ended December 31, 2025. Vericel is a commercial-stage biopharmaceutical company focused on advanced therapies for sports medicine and severe burn care. The company operates in a single reportable segment and markets three FDA-approved products in the U.S.: MACI (autologous cellularized scaffold for knee cartilage repair), Epicel (permanent skin replacement for severe burns), and NexoBrid (enzymatic eschar removal agent). In August 2024, the FDA approved an arthroscopic delivery method for MACI (MACI Arthro), and in August 2024, expanded NexoBrid's indication to include pediatric patients.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: Cash & Investments includes $100.1M cash/cash equivalents, $37.4M short-term investments, and $61.4M long-term investments.

Material Changes vs. Prior Period

• Revenue Growth: Driven primarily by a 21.4% increase in MACI revenue ($239.5M) due to volume and price growth, and a 42.4% increase in NexoBrid revenue ($4.7M). This was partially offset by a 12.4% decline in Epicel revenue ($32.1M) due to lower volume.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 16.9% to $167.0M, driven by higher headcount, stock-based compensation, marketing programs, and depreciation related to the new Burlington, MA facility. R&D expenses increased 11.2% to $27.6M, primarily for headcount and technical transfer to the new facility.
• Profitability: The company achieved its second consecutive year of net income, with operating income more than doubling due to revenue growth outpacing expense increases and a fixed-cost manufacturing structure.
• Balance Sheet: Accounts receivable increased significantly ($23.3M) due to higher sales volume. Inventory remained relatively stable at $17.6M.

Guidance, Outlook, and Risks

Outlook and Strategy: Management expects to continue investing in MACI growth initiatives, including the commercialization of MACI Arthro and the MASCOT clinical trial for ankle cartilage defects (initiated Q4 2025). The company anticipates commercializing MACI in the United Kingdom in 2027. The new Burlington manufacturing facility is complete and undergoing validation to become the primary production site.

Key Risks and Contingencies:

• Supply Chain Disruption: NexoBrid is manufactured by MediWound in Israel. Geopolitical conflicts in the Middle East pose a risk to supply, though the company currently maintains ample U.S. inventory.
• Regulatory & Reimbursement: Success depends on maintaining FDA approvals and third-party payer reimbursement. The company faces uncertainty regarding U.S. trade policies, tariffs, and potential "Most Favored Nation" (MFN) drug pricing initiatives under the current administration.
• Manufacturing Transition: Delays in qualifying the Burlington facility could limit the ability to meet future demand for MACI and Epicel.
• Seasonality: MACI sales are historically seasonal, with approximately 34% of annual volume occurring in the fourth quarter.

Investor Verification Checklist

• MACI Arthro Adoption: Verify the rate of surgeon adoption and volume contribution from the new arthroscopic delivery method launched in late 2024.
• NexoBrid Supply Chain: Monitor updates on MediWound's manufacturing capabilities in Israel and the status of U.S. inventory levels amidst geopolitical tensions.
• Burlington Facility Validation: Confirm the timeline for FDA qualification of the new manufacturing facility to ensure capacity for future growth.
• Reimbursement Trends: Assess the impact of potential MFN pricing policies and payer coverage changes on MACI and NexoBrid net prices.
• MASCOT Trial Progress: Track enrollment and preliminary data from the ankle cartilage defect trial initiated in Q4 2025.